Aymara Cabrera-Muñoz

Dr. Aymara Cabrera-Muñoz

Center for Protein Studies/ Department of Biochemestry, University of Havana, Havana, La Habana, Cuba
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Protein Expression and Purification
Verified
Journal Article
Closed access
ESEmir Salas-Sarduy
Emir Salas-Sarduy
ACAymara Cabrera-Muñoz
Aymara Cabrera-Muñoz
STSebastián Alejandro Trejo
Sebastián Alejandro Trejo
MPMaría de Los A. Chavéz Planes
María de Los A. Chavéz Planes

1 November 2013 in Experimental Parasitology
Verified
Journal Article
Closed access
ESEmir Salas-Sarduy
Emir Salas-Sarduy
ACAymara Cabrera-Muñoz
Aymara Cabrera-Muñoz
Ana CauerhffAna Cauerhff
Ana Cauerhff
YGYamile González-González
Yamile González-González
STSebastián A. Trejo
Sebastián A. Trejo
JCJuan José Cazzulo
Juan José Cazzulo

1 June 2019 in Journal of Structural Biology
Verified
Journal Article
Closed access
ACAymara Cabrera-Muñoz
Aymara Cabrera-Muñoz
PVPedro A. Valiente
Pedro A. Valiente
LRLaritza Rojas
Laritza Rojas
MRMaday Alonso del Rivero
Maday Alonso del Rivero
JPJosé R. Pires
José R. Pires

1 July 2021 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
LRLaritza Rojas
Laritza Rojas
ACAymara Cabrera-Muñoz
Aymara Cabrera-Muñoz
DPDayrom Gil Pradas
Dayrom Gil Pradas
JGJessica B. González
Jessica B. González
MRMaday Alonso del Rivero
Maday Alonso del Rivero
YGYamile González-González
Yamile González-González
CmPI-II is a Kazal-type tight-binding inhibitor isolated from the Caribbean snail Cenchritis muricatus. This inhibitor has an unusual specificity in the Kazal family, as it can inhibit subtilisin A (SUBTA), elastases and trypsin. An alanine in CmPI-II P1 site could avoid trypsin inhibition while improving/maintaining SUBTA and elastases inhibition. Thus, an alanine mutant of this position (rCmPI-II R12A) was obtained by site-directed mutagenesis. The gene cmpiR12A was expressed in P. pastoris KM71H yeast. The recombinant protein (rCmPI-II R12A) was purified by the combination of two ionic exchange chromatography (1:cationic, 2 anionic) followed by and size exclusion chromatography. The N-terminal sequence obtained as well as the experimental molecular weight allowed verifying the identity of the recombinant protein, while the correct folding was confirmed by CD experiments. rCmPI-II R12A shows a slightly increase in potency against SUBTA and elastases. The alanine substitution at P1 site on CmPI-II abolishes the trypsin inhibition, confirming the relevance of an arginine residue at P1 site in CmPI-II for trypsin inhibition and leading to a molecule with more potentialities in biomedicine.

1 October 2016 in Protein Expression and Purification
Verified
Journal Article
Closed access
ACAymara Cabrera-Muñoz
Aymara Cabrera-Muñoz
LRLaritza Rojas
Laritza Rojas
DGDayrom F. Gil
Dayrom F. Gil
YGYamile González-González
Yamile González-González
MMManuel Mansur
Manuel Mansur
MRMaday Alonso del Rivero
Maday Alonso del Rivero

28 January 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ACAymara Cabrera-Muñoz
Aymara Cabrera-Muñoz
YGYusvel Sierra Gómez
Yusvel Sierra Gómez
GCGiovanni Covaleda Cortés
Giovanni Covaleda Cortés
MRMey L. Reytor
Mey L. Reytor
YGYamile González-González
Yamile González-González
MRMaday Alonso del Rivero
Maday Alonso del Rivero
Metallocarboxypeptidases are zinc-dependent peptide-hydrolysing enzymes involved in several important physiological and pathological processes. They have been a target of growing interest in the search for natural or synthetic compound binders with biomedical and drug discovery purposes, i.e., with potential as antimicrobials or antiparasitics. Given that marine resources are an extraordinary source of bioactive molecules, we screened marine invertebrates for new inhibitory compounds with such capabilities. In this work, we report the isolation and molecular and functional characterization of NpCI, a novel strong metallocarboxypeptidase inhibitor from the marine snail Nerita peloronta. NpCI was purified until homogeneity using a combination of affinity chromatography and RP-HPLC. It appeared as a 5921.557 Da protein with 53 residues and six disulphide-linked cysteines, displaying a high sequence similarity with NvCI, a carboxypeptidase inhibitor isolated from Nerita versicolor, a mollusc of the same genus. The purified inhibitor was determined to be a slow- and tight-binding inhibitor of bovine CPA (Ki = 1.1·× 10−8 mol/L) and porcine CPB (Ki = 8.15·× 10−8 mol/L) and was not able to inhibit proteases from other mechanistic classes. Importantly, this inhibitor showed antiplasmodial activity against Plasmodium falciparum in an in vitro culture (IC50 = 5.5 μmol/L), reducing parasitaemia mainly by inhibiting the later stages of the parasite’s intraerythrocytic cycle whilst having no cytotoxic effects on human fibroblasts. Interestingly, initial attempts with other related proteinaceous carboxypeptidase inhibitors also displayed similar antiplasmodial effects. Coincidentally, in recent years, a metallocarboxypeptidase named PfNna1, which is expressed in the schizont phase during the late intraerythrocytic stage of the parasite’s life cycle, has been described. Given that NpCI showed a specific parasiticidal effect on P. falciparum, eliciting pyknotic/dead parasites, our results suggest that this and related inhibitors could be promising starting agents or lead compounds for antimalarial drug discovery strategies.